📰 Ali Chartan News
Page 3 - Ali Chartan News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ali Chartan. Real-time updates on events, politics, business and more.
October 11, 2023
(2023-10-11 | NDAQ:NVAX) Novavax Advances Science Supporting Protein-based Vaccine Technology at IDWeek 2023 and World Vaccine Congress Europe 2023
October 10, 2023
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it has...
October 4, 2023
GAITHERSBURG, Md., Oct. 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™
October 3, 2023
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the...
September 8, 2023
GAITHERSBURG, Md., Sept. 8, 2023 /PRNewswire/ -- Novavax, Inc. , a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in...
September 8, 2023
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that Novavax...
August 22, 2023
Novavaxs 2023-2024 season COVID vaccine candidate induced neutralizing responses to emerging subvariants EG.5.1 and XBB.1.16.6 in addition to XBB.1.5, XBB.1.16 and XBB.2.3Upon regulatory approval,...
August 8, 2023
Second quarter total revenue of $424 million and net income of $58 million Executed new strategic partnering agreement with SK bioscience, including an equity...
June 15, 2023
Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and is manufacturing at commercial scale with the intent to be in market during the fall vaccination campaignNovavax... | June 15, 2023
June 15, 2023
Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and is manufacturing at commercial scale with the intent to be in market during the fall vaccination campaignNovavax